Subconiunctival Injection of Bevacizumabgor Corneal Neovascularization after Penetrating keratoplasty A Prospective Open Label Non-comparitive Study

Downloads

Published

2021-07-25

Keywords:

.

Dimensions Badge

Issue

Vol. 9 No. 01 (2021): UP JOURNAL OF OPHTHALMOLOGY

Section

Original Study

License

Copyright (c) 2023 UP JOURNAL OF OPHTHALMOLOGY

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

© UPJO, 2023 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.

Authors

  • Shefali Mazumder .
  • S.K Satsangi .
  • Sushma Chaurasia .

Abstract

Objectives: To evaluate the efficacy of sub conjunctival Anti-VEGF Bevacizumab in post keratoplasty corneal neo vascularization in terms of graft survival. 

Study design: Prospective, open label Non-comparitive study.

How to Cite

1.
Mazumder S, Satsangi S, Chaurasia S. Subconiunctival Injection of Bevacizumabgor Corneal Neovascularization after Penetrating keratoplasty A Prospective Open Label Non-comparitive Study. UPJO [Internet]. 2021 Jul. 25 [cited 2024 Oct. 17];9(01):14-9. Available from: https://upjo.org/index.php/upjo/article/view/379

Downloads

Download data is not yet available.